The investigation by28 established that inflammatory pathways play central roles in CAD development within CKD populations, leading to the identification of promising biomarkers, including glutamate cysteine ligase modifier subunit (GCLM) and nuclear protein 1 (NUPR1), for enhanced diagnostic and therapeutic applications. This evidence concerns the gene NUPR1 and chronic kidney disease.